– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its anti-thrombotic ALX-0081, has reached the primary endpoint of the current Phase Ib study,…
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS — Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint®’s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van ‘t Veer, from the Netherlands Cancer Institute, presented…
– Oxford – Chroma Therapeutics Limited, a leading European specialist cancer research company, announced today positive data from a Phase II study with its oral, once-daily experimental cancer therapy tosedostat (CHR-2797) in the treatment of patients with acute myeloid leukemia (AML)…
– Ghent, Belgium – Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has reached a milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a…
– Huntington Beach, CA, and AMSTERDAM, THE NETHERLANDS -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has initiated a double-blind, randomized, placebo-controlled Phase I study in healthy volunteers…
– SYMPHOGEN AND MEIJI SEIKA KAISHA LTD. ACHIEVE MILESTONE IN DISCOVERY COLLABORATION FOR RECOMBINANT POLYCLONAL ANTIBODY, SYM006 COPENHAGEN, Denmark and TOKYO, Japan – Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the…
– Results will be discussed at the European Antibody Congress in Geneva, December 2 and at the IBC’s International Conference on Antibody Engineering in San Diego, December 11. Copenhagen, Denmark – Symphogen A/S today announced that John Haurum, Chief Scientific Officer and Michael…
– STOCKHOLM, Sweden and COPENHAGEN, Denmark – Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN)…
– Munich, Germany – IDEA AG has recently presented results of a US phase III, 12-month clinical safety and efficacy study of Diractin® (ketoprofen in Transfersome® gel, formerly known as IDEA-033) in patients with osteoarthritis of both knees in comparison to oral naproxen (Study CL-033-III-05)…
– Novo Nordisk A/S (“NN”) and Innate Pharma (“IPH”) have reached an agreement by which IPH is granted full development and commercial rights to IPH 2101 in exchange of full rights to IPH 2301 plus 2.5 million euros upfront payment, milestone payments and royalties on future sales of…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, has initiated its first clinical trial, a Phase I study of its lead product candidate APD 405. Acacia is one of the few companies focused on supportive care, especially…
– HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare…
– Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits Ghent, BELGIUM - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a…
– HUNTINGTON BEACH, CA, and AMSTERDAM, The Netherlands / Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint®, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor…
– Munich, Germany – IDEA AG today publicised two additional phase III clinical studies with Diractin® (ketoprofen in Transfersome® carriers, formerly known as IDEA-033) and successful completion of two long-term studies with the product. In Q2 2008, IDEA started screening and enrolment…
– Waltham, Mass., BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel diagnostics, today announced the publication* of the biomarker discovery study yielding its novel diagnostic candidate for the detection of ruptured plaque, the…
– Funds to accelerate launch of diagnostic products to enable Biomarker-Guided Medicine Waltham, Mass., BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and…
– FREISING-WEIHENSTEPHAN and JENA, Germany, July 16 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, and Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, announced today…
– COPENHAGEN, Denmark and STOCKHOLM, Sweden – Symphogen A/S and Biovitrum AB (publ) (STO:BVT) today announced the recruitment of the first patient into a Phase II clinical trial, initiated in June, to evaluate the safety and efficacy, and explore the dose range of Sym001 in Idiopathic…
– AMSTERDAM, The Netherlands and BARCELONA, Spain - Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia’s signature cancer diagnostic services. MammaPrint, a prognostic test that uses a 70-gene signature to indicate…
– Santaris Pharma A/S, the Danish biopharmaceutical company, announced today that Søren Tulstrup, previously Vice President, Global Human Health at Merck & Co., Inc., has been appointed President & Chief Executive Officer, effective July 1, 2008. He takes over as CEO from Dr. Keith…
– SUNNYVALE, Calif., June 18, 2008 -- FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer.…
– Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets. In this collaboration, Symphogen will apply its proprietary Symplex(TM) antibody discovery…
– Amsterdam - MammaPrint® can reduce the use of chemotherapy in breast cancer treatment by a quarter Agendia’s MammaPrint® has been declared one of the four most pioneering healthcare innovations by the Dutch Innovation Platform. At the Healthcare summit, Minister Klink, chairman of…
– IDEA AG today announced that it has received two milestone payments under the US licensing agreement with Alpharma Ireland Limited for Diractin® (ketoprofen in Transfersome®, formerly known as IDEA-033). The total payment of $37 million was triggered by IDEA's reaching clinical as…
– STOCKHOLM, Sweden and COPENHAGEN, Denmark – Biovitrum AB (publ) (Ticker: STO:BVT) and Symphogen A/S today announced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation…
– Boston – BG Medicine, on behalf of the HRP Initiative, today announced that Takeda Pharmaceutical Company Limited (“Takeda”) has joined BG Medicine, Merck, AstraZeneca, and Philips as the newest member of the Initiative. The HRP Initiative is a pre-competitive industry collaboration…
– FREISING-WEIHENSTEPHAN, Germany - Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round. Led by new investor OrbiMed Advisors LLC, a major global fund dedicated…
– SAN DIEGO, /PRNewswire/ - Conatus Pharmaceuticals Inc. today announced the appointment of Anthony "Tony" W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has received an undisclosed milestone payment from Novartis for an exclusive research license…
– Danish population study offers opportunity for discovery of blood biomarkers in individuals who suffer a heart attack without prior history of cardiovascular disease. BG Medicine today announced that it has entered into a research collaboration agreement with the Copenhagen General…
– Biovitrum and Symphogen are developing a recombinant, polyclonal antibody (Sym001) for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and prophylaxis of rhesus hemolytic disease of the newborn. The phase I clinical trial was initiated in March 2007 and the results from…
– BG Medicine plans to develop and commercialize diagnostic tests to aid in early diagnosis of acute cardiac and cerebral disorders Waltham, Mass. and Maastricht, The Netherlands. BG Medicine, Inc. (BG Medicine) and ACS Biomarker B.V. (ACS Biomarker) today announced that they have…